Literature DB >> 19365156

Impact and management of breakthrough pain in cancer.

Giovambattista Zeppetella1.   

Abstract

PURPOSE OF REVIEW: To outline the impact of breakthrough pain, the evidence for the current management and new treatment options that are becoming available. RECENT
FINDINGS: Breakthrough pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. Despite its self-limiting nature, breakthrough pain can place significant physical, psychological, and economic burdens on both patients and their carers. The successful management breakthrough pain may require a combination of pharmacological and nonpharmacological treatment strategies; supplemental analgesia, known as rescue medication, is a common pharmacological treatment option. The ideal rescue medication should have a rapid onset, good efficacy, relatively short duration of action, and minimal adverse effects and is best administered before or soon after breakthrough pain has started. Although oral opioids are commonly used, there is increasing evidence that transmucosal opioids may be more effective.
SUMMARY: Breakthrough is a common heterogeneous pain state that can have a devastating impact on both patients and carers. Despite the growing literature on breakthrough pain, there are still many aspects yet to be addressed including an urgent need to standardize terminology, for carefully designed epidemiological studies and for well designed controlled trials comparing the different treatment options.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19365156     DOI: 10.1097/SPC.0b013e3283260658

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  20 in total

Review 1.  Bone cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Alice S Ferng; Christopher P Geffre; Patrick W Mantyh
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

Review 2.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

4.  Effect of dose escalation with single opioid, fentanyl matrix in patients not controlling cancer pain: a multicenter, prospective, observational study in Korea.

Authors:  Sung Ae Koh; Kyung Hee Lee; Mi Jung Kim; Kyu Taek Lee; Seung Woo Park; Seung Hyun Nam; Hun Mo Ryoo
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

5.  Time to pain relief after immediate-release morphine in episodic pain: the TIME study.

Authors:  Claudio Lo Presti; Alessandro Roscetti; Davide Muriess; Massimo Mammucari
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

6.  Cancer pain physiology.

Authors:  Sarah Falk; Kirsty Bannister; Anthony H Dickenson
Journal:  Br J Pain       Date:  2014-11

Review 7.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

8.  A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level.

Authors:  Qi Gui; Chengcheng Xu; Liang Zhuang; Shu Xia; Yu Chen; Ping Peng; Shiying Yu
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

9.  Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey.

Authors:  Jinyoung Shin; Do Yeun Kim; Juneyoung Lee; Youn Seon Choi; In Gyu Hwang; Sun Kyung Baek; Min Seok Seo; Jae Yong Shim
Journal:  J Cancer Educ       Date:  2018-04       Impact factor: 2.037

10.  A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain.

Authors:  Juan Miguel Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Haili Xu; Alice S Ferng; Gregory Dussor; Todd W Vanderah; Patrick W Mantyh
Journal:  Bone       Date:  2009-09-18       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.